Cassava stops Alzheimer's program as simufilam fails another phase 3
Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in Alzheimer’s disease. Months after seeing one phase 3 trial fail, the biotech is planning to stop development altogether after chalking up another late-stage flop.
While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...
(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...
After Cassava Sciences (SAVA) announced that top-line results from its ReFocus-ALZ Phase 3 trial with simufilam in patients with ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Rest of World on MSN2d
What you need to know about Africa’s first AI factoryNvidia and Zimbabwean billionaire Strive Masiyiwa join hands to bring supercomputer technology to the continent.
Cassava Technologies is set to roll out Nvidia’s artificial intelligence software at its South African data centers by June, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback